128 related articles for article (PubMed ID: 38291863)
1. Response to atezolizumab plus bevacizumab specific for lung and lymph node metastases affects survival of patients with HCC.
Yang J; Choi J; Choi WM; Kim KM; Lee HC; Shim JH
Liver Int; 2024 Apr; 44(4):907-919. PubMed ID: 38291863
[TBL] [Abstract][Full Text] [Related]
2. Characterization of response to atezolizumab + bevacizumab versus sorafenib for hepatocellular carcinoma: Results from the IMbrave150 trial.
Salem R; Li D; Sommer N; Hernandez S; Verret W; Ding B; Lencioni R
Cancer Med; 2021 Aug; 10(16):5437-5447. PubMed ID: 34189869
[TBL] [Abstract][Full Text] [Related]
3. Protocol of the RACB study: a multicenter, single-arm, prospective study to evaluate the efficacy of resection of initially unresectable hepatocellular carcinoma with atezolizumab combined with bevacizumab.
Okuno M; Ishii T; Ichida A; Soyama A; Takemura N; Hirono S; Eguchi S; Hasegawa K; Sasaki Y; Uemura K; Kokudo N; Hatano E
BMC Cancer; 2023 Aug; 23(1):780. PubMed ID: 37605169
[TBL] [Abstract][Full Text] [Related]
4. A case of hepatocellular carcinoma with "pseudoprogression" followed by complete response to atezolizumab plus bevacizumab.
Odagiri N; Tamori A; Kotani K; Motoyama H; Kawamura E; Hagihara A; Fujii H; Uchida-Kobayashi S; Enomoto M; Kawada N
Clin J Gastroenterol; 2023 Jun; 16(3):392-396. PubMed ID: 36739366
[TBL] [Abstract][Full Text] [Related]
5. Comparison of prognostic impact of atezolizumab plus bevacizumab versus lenvatinib in patients with intermediate-stage hepatocellular carcinoma.
Tada T; Kumada T; Hiraoka A; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Tada F; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Kosaka H; Naganuma A; Matono T; Aoki T; Kuroda H; Yata Y; Koizumi Y; Nakamura S; Kaibori M; Iijima H; Hiasa Y; Kudo M;
Liver Int; 2024 Jan; 44(1):113-124. PubMed ID: 37789669
[TBL] [Abstract][Full Text] [Related]
6. Impact of first-line systemic therapy with atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.
Tada T; Kumada T; Hiraoka A; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Tada F; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Kosaka H; Naganuma A; Matono T; Koizumi Y; Nakamura S; Kaibori M; Iijima H; Hiasa Y;
J Gastroenterol Hepatol; 2023 Aug; 38(8):1389-1397. PubMed ID: 37231943
[TBL] [Abstract][Full Text] [Related]
7. Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma.
Vithayathil M; D'Alessio A; Fulgenzi CAM; Nishida N; Schönlein M; von Felden J; Schulze K; Wege H; Saeed A; Wietharn B; Hildebrand H; Wu L; Ang C; Marron TU; Weinmann A; Galle PR; Bettinger D; Bengsch B; Vogel A; Balcar L; Scheiner B; Lee PC; Huang YH; Amara S; Muzaffar M; Naqash AR; Cammarota A; Zanuso V; Pressiani T; Pinter M; Cortellini A; Kudo M; Rimassa L; Pinato DJ; Sharma R
Hepatol Int; 2023 Aug; 17(4):904-914. PubMed ID: 37005953
[TBL] [Abstract][Full Text] [Related]
8. Prognosis and treatment pattern of advanced hepatocellular carcinoma after failure of first-line atezolizumab and bevacizumab treatment.
Chen CT; Feng YH; Yen CJ; Chen SC; Lin YT; Lu LC; Hsu CH; Cheng AL; Shao YY
Hepatol Int; 2022 Oct; 16(5):1199-1207. PubMed ID: 35986846
[TBL] [Abstract][Full Text] [Related]
9. Pretreatment Positron Emission Tomography with 18F-Fluorodeoxyglucose May Be a Useful New Predictor of Early Progressive Disease following Atezolizumab plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma.
Kawamura Y; Kobayashi M; Shindoh J; Matsumura M; Okubo S; Muraishi N; Fujiyama S; Hosaka T; Saitoh S; Sezaki H; Akuta N; Suzuki F; Suzuki Y; Ikeda K; Arase Y; Hashimoto M; Kumada H
Oncology; 2022; 100(6):320-330. PubMed ID: 35231914
[TBL] [Abstract][Full Text] [Related]
10. Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictive Marker of Response to Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma.
Eso Y; Takeda H; Taura K; Takai A; Takahashi K; Seno H
Curr Oncol; 2021 Oct; 28(5):4157-4166. PubMed ID: 34677270
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of Patients with Child-Pugh B and Unresectable Hepatocellular Carcinoma Undergoing First-Line Systemic Treatment with Sorafenib, Lenvatinib, or Atezolizumab Plus Bevacizumab.
Kikugawa C; Uchikawa S; Kawaoka T; Kinami T; Yano S; Amioka K; Naruto K; Ando Y; Yamaoka K; Tsuge M; Kosaka Y; Ohya K; Mori N; Takaki S; Tsuji K; Kouno H; Kohno H; Morio K; Moriya T; Nonaka M; Aisaka Y; Masaki K; Honda Y; Naeshiro N; Hiramatsu A; Aikata H; Oka S
Oncology; 2024; 102(3):239-251. PubMed ID: 37729889
[TBL] [Abstract][Full Text] [Related]
12. Atezolizumab plus bevacizumab in advanced hepatocellular carcinoma after treatment failure with multikinase inhibitors.
Haghnejad V; Muller M; Blaise L; Gerolami R; Bouattour M; Assenat E; Manfredi S; Peron JM; Burcheri-Curatolo A; Lopez A; Ressiot E; Nahon P; Bronowicki JP
Dig Liver Dis; 2023 Jul; 55(7):938-944. PubMed ID: 37019737
[TBL] [Abstract][Full Text] [Related]
13. Safety and Feasibility of Combining On-Demand Selective Locoregional Treatment with First-Line Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma.
Nakabori T; Higashi S; Abe Y; Mukai K; Ikawa T; Konishi K; Maeda N; Nakanishi K; Hasegawa S; Wada H; Ohkawa K
Curr Oncol; 2024 Mar; 31(3):1543-1555. PubMed ID: 38534950
[TBL] [Abstract][Full Text] [Related]
14. Higher objective responses by hepatic arterial infusion chemotherapy following atezolizumab and bevacizumab failure than when used as initial therapy in hepatocellular carcinoma: a retrospective study.
Yoo JS; Kim JH; Cho HS; Han JW; Jang JW; Choi JY; Yoon SK; Kim S; Oh JS; Chun HJ; Sung PS
Abdom Radiol (NY); 2024 Apr; ():. PubMed ID: 38678485
[TBL] [Abstract][Full Text] [Related]
15. Pathological complete response of hepatocellular carcinoma confirmed by conversion hepatectomy following atezolizumab plus bevacizumab therapy: a case report and literature review.
Sato S; Aoki T; Matsumoto T; Shiraki T; Mori S; Iso Y; Nemoto T; Onishi T; Iijima M; Ishida K
Clin J Gastroenterol; 2024 Apr; 17(2):292-299. PubMed ID: 38071671
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the profiles of first-line PD-1/PD-L1 inhibitors for advanced NSCLC lacking driver gene mutations: a systematic review and Bayesian network meta-analysis.
Wenfan F; Manman X; Xingyuan S; Zeyong J; Jian Z; Lu D
Ther Adv Chronic Dis; 2023; 14():20406223231189224. PubMed ID: 37841212
[TBL] [Abstract][Full Text] [Related]
17. First-Line Atezolizumab Plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis.
Chiang CL; Chan SK; Lee SF; Choi HC
Cancers (Basel); 2021 Feb; 13(5):. PubMed ID: 33668100
[TBL] [Abstract][Full Text] [Related]
18. Association of High Levels of Antidrug Antibodies Against Atezolizumab With Clinical Outcomes and T-Cell Responses in Patients With Hepatocellular Carcinoma.
Kim C; Yang H; Kim I; Kang B; Kim H; Kim H; Lee WS; Jung S; Lim HY; Cheon J; Chon HJ
JAMA Oncol; 2022 Dec; 8(12):1825-1829. PubMed ID: 36264560
[TBL] [Abstract][Full Text] [Related]
19. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.
Galle PR; Finn RS; Qin S; Ikeda M; Zhu AX; Kim TY; Kudo M; Breder V; Merle P; Kaseb A; Li D; Mulla S; Verret W; Xu DZ; Hernandez S; Ding B; Liu J; Huang C; Lim HY; Cheng AL; Ducreux M
Lancet Oncol; 2021 Jul; 22(7):991-1001. PubMed ID: 34051880
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of atezolizumab plus bevacizumab combination therapy for hepatocellular carcinoma using contrast-enhanced ultrasonography.
Uchikawa S; Kawaoka T; Fujino H; Ono A; Nakahara T; Murakami E; Yamauchi M; Miki D; Imamura M; Aikata H
J Med Ultrason (2001); 2023 Jan; 50(1):57-62. PubMed ID: 36169740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
